Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Wayne Memorial Hospital
418
mi
from 43215
Goldsboro, NC
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Wayne Memorial Hospital
418
mi
from 43215
Goldsboro, NC
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Southeastern Medical Oncology Center-Jacksonville
473
mi
from 43215
Jacksonville, NC
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Southeastern Medical Oncology Center-Jacksonville
473
mi
from 43215
Jacksonville, NC
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Southeastern Medical Oncology Center-Wilson
404
mi
from 43215
Wilson, NC
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Southeastern Medical Oncology Center-Wilson
404
mi
from 43215
Wilson, NC
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
305
mi
from 43215
Winston-Salem, NC
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
305
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Baker City
1794
mi
from 43215
Baker City, OR
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Baker City
1794
mi
from 43215
Baker City, OR
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Ontario
1753
mi
from 43215
Ontario, OR
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Ontario
1753
mi
from 43215
Ontario, OR
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital-Cedar Crest
397
mi
from 43215
Allentown, PA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital-Cedar Crest
397
mi
from 43215
Allentown, PA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital - Muhlenberg
405
mi
from 43215
Bethlehem, PA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital - Muhlenberg
405
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
991
mi
from 43215
Houston, TX
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Baylor Saint Luke's Medical Center
995
mi
from 43215
Houston, TX
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Baylor Saint Luke's Medical Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Michael E. Debakey VA Medical Center
995
mi
from 43215
Houston, TX
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Michael E. Debakey VA Medical Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Cancer Care Center at Island Hospital
2021
mi
from 43215
Anacortes, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Cancer Care Center at Island Hospital
2021
mi
from 43215
Anacortes, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Saint Joseph Medical Center
2015
mi
from 43215
Bellingham, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Saint Joseph Medical Center
2015
mi
from 43215
Bellingham, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Harrison HealthPartners Hematology and Oncology-Bremerton
2020
mi
from 43215
Bremerton, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Harrison HealthPartners Hematology and Oncology-Bremerton
2020
mi
from 43215
Bremerton, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Highline Medical Center-Main Campus
2007
mi
from 43215
Burien, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Highline Medical Center-Main Campus
2007
mi
from 43215
Burien, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-Edmonds
2007
mi
from 43215
Edmonds, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Edmonds
2007
mi
from 43215
Edmonds, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute-Issaquah
1993
mi
from 43215
Issaquah, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute-Issaquah
1993
mi
from 43215
Issaquah, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
1856
mi
from 43215
Kennewick, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
1856
mi
from 43215
Kennewick, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance at EvergreenHealth
2001
mi
from 43215
Kirkland, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance at EvergreenHealth
2001
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Skagit Valley Hospital
2007
mi
from 43215
Mount Vernon, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Skagit Valley Hospital
2007
mi
from 43215
Mount Vernon, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Harrison HealthPartners Hematology and Oncology-Poulsbo
2021
mi
from 43215
Poulsbo, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Harrison HealthPartners Hematology and Oncology-Poulsbo
2021
mi
from 43215
Poulsbo, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-Ballard Campus
2009
mi
from 43215
Seattle, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Ballard Campus
2009
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Group Health Cooperative-Seattle
2005
mi
from 43215
Seattle, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Group Health Cooperative-Seattle
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-First Hill
2006
mi
from 43215
Seattle, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-First Hill
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
United General Hospital
2004
mi
from 43215
Sedro-Woolley, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
United General Hospital
2004
mi
from 43215
Sedro-Woolley, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Rockwood Clinic
1779
mi
from 43215
Spokane, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Rockwood Clinic
1779
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Wenatchee Valley Hospital and Clinics
1912
mi
from 43215
Wenatchee, WA
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Wenatchee Valley Hospital and Clinics
1912
mi
from 43215
Wenatchee, WA
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
335
mi
from 43215
Milwaukee, WI
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Big Horn Basin Cancer Center
1361
mi
from 43215
Cody, WY
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Big Horn Basin Cancer Center
1361
mi
from 43215
Cody, WY
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Billings Clinic-Cody
1361
mi
from 43215
Cody, WY
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Billings Clinic-Cody
1361
mi
from 43215
Cody, WY
Click here to add this to my saved trials
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
492
mi
from 43215
Birmingham, AL
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Fairbanks Memorial Hospital
3032
mi
from 43215
Fairbanks, AK
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Fairbanks Memorial Hospital
3032
mi
from 43215
Fairbanks, AK
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Anaheim
1956
mi
from 43215
Anaheim, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Anaheim
1956
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Baldwin Park
1956
mi
from 43215
Baldwin Park, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Baldwin Park
1956
mi
from 43215
Baldwin Park, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Bellflower
1970
mi
from 43215
Bellflower, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Bellflower
1970
mi
from 43215
Bellflower, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Marin Cancer Care, Inc.
2109
mi
from 43215
Greenbrae, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Marin Cancer Care, Inc.
2109
mi
from 43215
Greenbrae, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Harbor City
1982
mi
from 43215
Harbor City, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Harbor City
1982
mi
from 43215
Harbor City, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Irvine
1959
mi
from 43215
Irvine, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Irvine
1959
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Fremont - Rideout Cancer Center
2038
mi
from 43215
Marysville, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Fremont - Rideout Cancer Center
2038
mi
from 43215
Marysville, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Panorama City
1978
mi
from 43215
Panorama City, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Panorama City
1978
mi
from 43215
Panorama City, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Riverside
1936
mi
from 43215
Riverside, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Riverside
1936
mi
from 43215
Riverside, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Mission
1949
mi
from 43215
San Diego, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Mission
1949
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Zion
1944
mi
from 43215
San Diego, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Zion
1944
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Marcos
1941
mi
from 43215
San Marcos, CA
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Marcos
1941
mi
from 43215
San Marcos, CA
Click here to add this to my saved trials